Avacta Group (AVCT) News Today → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free AVCT Stock Alerts GBX 47.20 -1.10 (-2.28%) (As of 04:32 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAvacta Group (LON:AVCT) Shares Pass Below 200 Day Moving Average of $98.87americanbankingnews.com - April 30 at 3:28 AMUpdated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024finance.yahoo.com - March 6 at 4:53 PMAvacta Group: Appointment of Chief Business Officerfinanznachrichten.de - December 19 at 9:39 AMAppointment of Chief Business Officerfinance.yahoo.com - December 19 at 9:39 AMALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Datafinance.yahoo.com - December 13 at 8:18 AMAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Boardfinance.yahoo.com - October 23 at 8:43 AMIf I’d invested £1,000 in Avacta shares 5 years ago, here’s how much I’d have nowmsn.com - September 11 at 8:33 AMAvacta Group Share Chatlse.co.uk - August 11 at 1:36 AMAvacta Completes Fifth Dose Escalation in AVA6000 Phase 1 Clinical Studymarketwatch.com - June 21 at 9:36 AMAvacta Group plc: Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Studyfinanznachrichten.de - June 21 at 9:36 AMAvacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Studyfinance.yahoo.com - June 21 at 9:36 AMAvacta Group Says No Fundraising Imminent; Shares Risemarketwatch.com - June 19 at 9:25 AMAVCT.L - Avacta Group Plcuk.finance.yahoo.com - June 6 at 9:59 PMFirst Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Studyfinance.yahoo.com - April 27 at 7:44 AMAvacta Group plc: Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Studyfinanznachrichten.de - April 5 at 8:49 AMAvacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Divisionfinance.yahoo.com - March 28 at 9:57 AMIs the Avacta share price dip a buying opportunity?msn.com - March 16 at 12:57 PMBlock Listing Application to AIMlse.co.uk - January 17 at 2:33 PMAvacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 58% of the companyfinance.yahoo.com - October 21 at 8:57 AMAvacta Group Plc (AVCT.L)uk.finance.yahoo.com - October 1 at 3:44 PMAvacta's AVA6000 Gets FDA Orphan Drug Designation To Treat Soft Tissue Sarcoma; Stock Upnasdaq.com - September 5 at 7:34 AMLG Chem Renews License Triggering Payment to Avactafinance.yahoo.com - June 30 at 5:18 AMAffyXell Expands its Strategic Partnership With...benzinga.com - May 16 at 9:40 PMAvacta full-year results push shares higherproactiveinvestors.com - April 6 at 7:32 AMIs Avacta Group (LON:AVCT) In A Good Position To Invest In Growth?finance.yahoo.com - March 19 at 3:43 AMWhat’s next for the Avacta share price?uk.finance.yahoo.com - March 17 at 4:39 PMThe Avacta share price: buy or avoid like the plague?uk.news.yahoo.com - March 1 at 6:40 PMAvacta Group selects second pre|CISION drug candidate for developmentmsn.com - January 18 at 8:46 AMAvacta Selects Second pre|CISION™ Pro-drug Candidate for Developmentfinance.yahoo.com - January 18 at 8:46 AMAvacta pauses sales of COVID-19 antigen test to improve Omicron sensitivityreuters.com - January 10 at 2:52 PMUK Stocks Factors to watch on Jan. 10reuters.com - January 10 at 4:52 AMAvacta pauses sales of COVID-19 antigen test to boost Omicron sensitivitymsn.com - January 10 at 4:52 AMAvacta Group PLC : Change of auditormarkets.businessinsider.com - December 16 at 11:15 PMWhat’s going on with the Avacta share price?fool.co.uk - December 15 at 10:24 AMAvacta Group plc: Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000finanznachrichten.de - November 29 at 10:17 AMAvacta Group (LSE:AVCT)fool.co.uk - August 20 at 8:41 AMAvacta doses first patient in chemotherapy medication triallse.co.uk - August 11 at 7:13 AMAvacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trialfinance.yahoo.com - August 11 at 7:13 AM Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden out June 13; Kamala won’t replace him? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. AVCT Media Mentions By Week AVCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVCT News Sentiment▼-0.140.34▲Average Medical News Sentiment AVCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVCT Articles This Week▼20▲AVCT Articles Average Week Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arix Bioscience News hVIVO News Futura Medical News Oxford Biomedica News Scancell News Faron Pharmaceuticals Oy News Bioventix News Poolbeg Pharma News e-therapeutics News Arecor Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AVCT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarProtect Your Bank Account Before It’s Too LateWeiss RatingsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsJeff Bezos Just Humiliated Elon MuskInvestorPlaceElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
